Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs.
Atsuto MouriKyoichi KairaOu YamaguchiKousuke HashimotoYu MiuraAyako ShionoShun ShinomiyaHisao ImaiKunihiko KobayashiHiroshi KagamuPublished in: Journal of clinical medicine (2021)
Patients administered systemic steroids for irAEs due to PD-1 blockade treatment exhibited shorter PFS than those who were not. Systemic steroids might affect survival after PD-1 blockade even for patients who once acquired its clinical benefit.